Table 3.
Treatment and prognosis of the 47 reported in case series/reports.
| Parameter | Value | |
|---|---|---|
| Pembrolizumab management when BP diagnosed(43)a |
Discontinued immediately | 20(46.51%) |
| Discontinued after a period of time for continuous treatment by pembrolizumab | 7(16.28%) | |
| Continued treatment | 4(9.30%) | |
| Temporarily discontinued then reinitiated | 4(9.30%) | |
| Onset after the cessation of pembrolizumab | 8(18.60%) | |
| Treatment(47)a | Topical steroid treatment | 35(74.47%) |
| Systemic treatment | 43(91.49%) | |
| Systemic corticosteroid treatment | 42(89.36%) | |
| Nonbiologic treatments | 21(44.68%) | |
| Tetracyclines | 12(25.53%) | |
| Niacinamide | 5(10.64%) | |
| Dapsone | 2(4.26%) | |
| Mycophenolate mofetil | 2(4.26%) | |
| Cyclophosphamide | 1(2.13%) | |
| Methotrexate | 1(2.13%) | |
| Hydroxyzine | 1(2.13%) | |
| Immunoglobulin | 1(2.13%) | |
| Biologic treatments | 5(10.64%) | |
| Rituximab | 3(6.38%) | |
| Dupilumab | 1(2.13%) | |
| Infliximab | 1(2.13%) | |
| BP remission time | Median time (months) | 2(0.3,15)b |
| BP outcome(47)a | Partial to complete remission | 37(78.72%) |
| Discontinued immediately | 16(34.04%) | |
| Discontinued after a period of time for continuous treatment by pembrolizumab | 6(12.77%) | |
| Continued treatment | 4(8.51%) | |
| Temporarily discontinued then reinitiated | 3(6.38%) | |
| Onset after the cessation of pembrolizumab | 5(10.64%) | |
| No information was available on whether or not to discontinue the pembrolizumab | 3(6.38%) | |
| Relapse/refractory symptomsc | 9(19.15%) | |
| Discontinued immediately | 3(6.38%) | |
| Discontinued after a period of time for continuous treatment by pembrolizumab | 1(2.13%) | |
| Temporarily discontinued then reinitiated | 1(2.13%) | |
| Onset after the cessation of pembrolizumab | 3(6.38%) | |
| No information was available on whether or not to discontinue the pembrolizumab | 1(2.13%) | |
| Not report | ||
| Discontinued immediately | 1(2.13%) | |
| Treatment response of pembrolizumab (27)a | Complete response, partial response or stable disease | 17(62.96%) |
| Progressive disease | 9(33.33%) | |
| No response | 1(3.70%) |
BP, bullous pemphigoid.
aIndicates the number of 47 patients for whom information on the treatment and prognosis was provided.
bMedian (minimum, maximum).
Includes patients who had appeared flares of BP on attempted tapering of systemic glucocorticoids.